Abstract:Experimentalallergic encephalomyelitis(EAE) is an animal model for inflammatory demyelinating autoimmune disease, i.e., multiple sclerosis (MS). In the present study, we investigated the antineuroinflammatory/neuroprotective effects of C16, an alpha upsilon beta 3 integrin-binding peptide, and recombinant rat ciliary neurotrophic factor (CNTF), a cytokine that was originally identified as a survival factor for neurons, in an acute rodent EAE model. In this model, C16 peptide was injected intravenously every day for 2 weeks, and CNTF was delivered into the cerebral ventricles with Alzet miniosmotic pumps. Disease severity was assessed weekly using a scale ranging from 0 to 5. Multiple histological and molecular biological assays were employed to assess inflammation, axonal loss, neuronal apoptosis, white matter demyelination, and gliosis in the brain and spinal cord of different groups. Our results showed that the EAE induced rats revealed a significant increase in inflammatory cells infiltration, while C16 treatment could inhibit the infiltration of leukocytes and macrophages down to 2/3-1/3 of vehicle treated EAE control (P < 0.05). The delayed onset of disease, reduced clinical score (P < 0.01) in peak stage and more rapid recovery also were achieved in C16 treated group. Besides impairing inflammation, CNTF treatment also exerted direct neuroprotective effects, decreasing demyelination and axon loss score (P < 0.05 versus vehicle treated EAE control), and reducing the neuronal death from 40 to 50% to 10 to 20% (P < 0.05). Both treatments suppressed the expression of cytokine tumor necrosis factor-alpha and interferon-gamma when compared with the vehicle control (P < 0.05). Combined treatment with C16 and CNTF produced more obvious functional recovery and neuroprotective effects than individually treatment (P < 0.05). These results suggested that combination treatment with C16 and CNTF, which target different neuroprotection pathways, may be an effective therapeutic alternative to traditional therapy.

Effect of a Cyclic Heptapeptide Based on the Human CD4 Domain 1 CC′ Loop Region on Murine Experimental Allergic Encephalomyelitis: Inhibition of Both Primary and Secondary Responses

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

An Organic CD4 Inhibitor Reduces the Clinical and Pathological Symptoms of Acute Experimental Allergic Encephalomyelitis

Dose-dependent anti-inflammatory and neuroprotective effects of an α β 3 integrin-binding peptide

Cd8 Alpha+ Dendritic Cells And Immune Protection From Experimental Allergic Encephalomyelitis

Neuroprotective effects of a novel peptide through the Rho-integrin-Tie2 and PI3K/Akt pathways in experimental autoimmune encephalomyelitis model

Blocking Initial Infiltration of Pioneer Cd8(+) T-Cells into the Cns Via Inhibition of Shp-2 Ameliorates Experimental Autoimmune Encephalomyelitis in Mice

The Complexity of Cytokine Treatment in Ongoing EAE Induced with MBP Peptide 68–86 in Lewis Rats

Combination of Apoptotic T Cell Induction and Self-Peptide Administration for Therapy of Experimental Autoimmune Encephalomyelitis

High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis

CD24 and Myosin Light Polypeptide 2 Are Involved in Prevention of Experimental Autoimmune Encephalomyelitis by Myelin Basic Protein-Pulsed Dendritic Cells.

Major Histocompatibility Complex-Controlled Protective Influences on Experimental Autoimmune Encephalomyelitis Are Peptide Specific.

An Ανβ3 Integrin-Binding Peptide Ameliorates Symptoms of Chronic Progressive Experimental Autoimmune Encephalomyelitis by Alleviating Neuroinflammatory Responses in Mice.

A Novel Aza-MBP Altered Peptide Ligand for the Treatment of Experimental Autoimmune Encephalomyelitis

Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis

Combined Nasal Administration of Encephalitogenic Myelin Basic Protein Peptide 68–86 and IL-10 Suppressed Incipient Experimental Allergic Encephalomyelitis in Lewis Rats

Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis

Bioactive Peptide Design Based on Protein Surface Epitopes: A CYCLIC HEPTAPEPTIDE MIMICS CD4 DOMAIN 1 CC′ LOOP AND INHIBITS CD4 BIOLOGICAL FUNCTION

CCDC134 Ameliorated Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells